Limitations, agreements, and source contact

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients · Source last updated 2020-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

limitations And Caveats

description

Study is terminated and long-term follow-up ended due to Sponsor decision.

point Of Contact

email

trials@oncopeptides.com

organization

Oncopeptides AB

phone

+4686152040

title

Eva Nordström

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice